Clinical Trial ProgressThe Company is nearing a pivotal event with the readout of their first-in-human, preliminary Phase 1 dose escalation study for a basket of solid tumors treated with PYX-201, anticipated to be a major stock moving event.
Financial PositionPyxis had approximately $157M in cash and cash equivalents at the end of 2Q24, which the company has sufficient fund to support.
Innovative Drug DesignPYX-201 was developed using Pfizer’s FACT platform, which enables site-specific conjugation, highlighting its advanced and precise design features.